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Guidelines for the Management of Severe Traumatic
Brain Injury: 2020 Update of the Decompressive
Craniectomy Recommendations
When the fourth edition of the Brain Trauma Foundation’s Guidelines for the Management
of Severe Traumatic Brain Injury were finalized in late 2016, it was known that the results
of the RESCUEicp (Trial of Decompressive Craniectomy for Traumatic Intracranial Hypertension) randomized controlled trial of decompressive craniectomy would be public after
the guidelines were released. The guideline authors decided to proceed with publication but to update the decompressive craniectomy recommendations later in the spirit
of “living guidelines,” whereby topics are updated more frequently, and between new
editions, when important new evidence is published. The update to the decompressive
craniectomy chapter presented here integrates the findings of the RESCUEicp study as
well as the recently published 12-mo outcome data from the DECRA (Decompressive
Craniectomy in Patients With Severe Traumatic Brain Injury) trial. Incorporation of these
publications into the body of evidence led to the generation of 3 new level-IIA recommendations; a fourth previously presented level-IIA recommendation remains valid and has
been restated. To increase the utility of the recommendations, we added a new section
entitled Incorporating the Evidence into Practice. This summary of expert opinion provides
important context and addresses key issues for practitioners, which are intended to help
the clinician utilize the available evidence and these recommendations.
The full guideline can be found at: https://braintrauma.org/guidelines/guidelines-for-themanagement-of-severe-tbi-4th-ed#/.
KEY WORDS: Traumatic brain injury, Head injury, Guideline, Fourth edition, Brain Trauma Foundation, Severe,
Decompressive craniectomy, Craniectomy, Decompression, Surgery
Neurosurgery 87:427–434, 2020
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T

reatment of intracranial pressure (ICP)
elevation is central to the management
of patients with severe traumatic brain
injury (TBI).1-3 The volume of the intracranial
contents often increases following TBI as a
result of hemorrhage, cerebral edema, and
hydrocephalus. This can lead to an injurious
shift of the brain–termed herniation. Moreover,
the increase in volume within the rigid skull
ABBREVIATIONS: DC, decompressive craniectomy;
GOS-E, Glasgow Outcome Scale–Extended; ICP,
intracranial pressure; ICU, intensive care unit; OR,
odds ratio; RCT, randomized controlled trial; SIBICC,
Seattle International severe traumatic Brain Injury
Consensus Conference; TBI, traumatic brain injury
Supplemental digital content is available for this article at
www.neurosurgery-online.com.
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can increase ICP leading to a compartment
syndrome4,5 which impedes or prevents the flow
of blood to the brain.3,6,7 The ensuing cerebral
ischemia can ultimately result in disability or
death.
The temporary removal of a large portion
of skull–termed decompressive craniectomy
(DC)–has long been part of the neurosurgeon’s
armamentarium for treating ICP elevation
resulting from TBI.8 Primary DC occurs when
the bone flap is not replaced when an intracranial
mass lesion is evacuated early after a head trauma.
Secondary DC involves the removal of the bone
flap later in the patient’s course–typically to
treat the elevation of ICP refractory to other
treatments. Over the last century, the use of
DC has been controversial. Technical aspects
of the surgery, timing, and patient selection
continue to be debated, and there has even been

VOLUME 87 | NUMBER 3 | SEPTEMBER 2020 | 427

HAWRYLUK ET AL

disagreement as to whether this procedure should be performed
at all. There had been hope that the RESCUEicp (Trial of
Decompressive Craniectomy for Traumatic Intracranial Hypertension) and DECRA (Decompressive Craniectomy in Patients
with Severe Traumatic Brain Injury) randomized controlled trials
(RCTs) would provide definitive guidance as to if and how this
technique should be employed. The results of these studies have
defied simple interpretations, however; DC remains controversial
despite the publication of these high-quality trials.9-11
In the fourth edition of the Brain Trauma Foundation’s Guidelines for the Management of Severe Traumatic Brain Injury
published in 2017,12 the lead chapter provided 2 level-IIA recommendations on the topic of DC. These recommendations served
to update the first published clinical practice guidelines for DC
provided in conjunction with the Brain Trauma Foundation’s
Guidelines for the Surgical Management of Traumatic Brain
Injury published in 2006.13 Here, we present an update of the
2017 recommendations following the adjudication and consideration of the evidence provided by RESCUEicp11 as well as
DECRA’s recently published 12-mo outcome data.10 One of
the previous recommendations was retained and 3 new level-IIA
recommendations are now provided on this topic.

UPDATED RECOMMENDATIONS
DECRA10 and RESCUEicp11 are higher quality studies whose
findings supersede those of lesser quality investigations. Though
both studied secondary DC for the treatment of refractory ICP
elevation, a key difference in the study protocols for DECRA10
and RESCUEicp11 is that they were designed to investigate conditions of early and late refractory ICP elevations, respectively.
Indeed, DECRA enrolled TBI patients with ICP above 20 mm
Hg for 15 min over a 1-h period despite the optimization of tier 1
treatments within the first 72 h of care (early), while RESCUEicp
enrolled patients with ICP greater than 25 mm Hg for 1 to 12 h
refractory to 2 tiers of treatment within 10 d of admission (late).
In constructing the recommendations that follow, we thus refer
to early and late refractory ICP elevations to reference conditions
similar to those studied in DECRA and RESCUEicp, respectively.
The addition of these studies to the available research evidence
is the basis for the following updated recommendations:
Level IIA–to improve mortality and overall outcomes
1. NEW–Secondary DC performed for late refractory ICP elevation
is recommended to improve mortality and favorable outcomes.
2. NEW–Secondary DC performed for early refractory ICP
elevation is not recommended to improve mortality and
favorable outcomes†.
3. A large frontotemporoparietal DC (not less than 12 × 15 cm
or 15 cm in diameter) is recommended over a small frontotemporoparietal DC for reduced mortality and improved neurological
outcomes in patients with severe TBI.
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Level IIA–for ICP control
4. NEW–Secondary DC, performed as a treatment for either early
or late refractory ICP elevation, is suggested to reduce ICP and
duration of intensive care, though the relationship between these
effects and favorable outcome is uncertain.

†Recommendation #2 should not be extrapolated to primary DC in
which the bone flap is left off when an intracranial mass lesion is
evacuated early after injury.
Changes from Prior Edition
The recommendations for DC in the fourth edition (2017)
were as follows:
Level IIA
1. “Bifrontal DC is not recommended to improve outcomes as
measured by the Glasgow Outcome Scale-Extended (GOSE) score at 6 months post-injury in severe TBI patients with
diffuse injury (without mass lesions), and with ICP elevation
to values > 20 mm Hg for more than 15 minutes within a
1-h period that are refractory to first-tier therapies. However,
this procedure has been demonstrated to reduce ICP and to
minimize days in the intensive care unit (ICU).
2. A large frontotemporoparietal DC (not less than 12 × 15 cm
or 15 cm diameter) is recommended over a small frontotemporoparietal DC for reduced mortality and improved neurologic outcomes in patients with severe TBI.”12
The first recommendation was based on the 6-mo outcomes
from DECRA.9 The second recommendation was based on 2
studies: Jiang et al (2005)14 and Qiu et al (2009).15
By virtue of the updated body of evidence, including 12-mo
outcome data from DECRA and RESCUEicp, both published
subsequent to the 2017 guidelines, we have removed the first
recommendation and restated the second. We also provide
3 new level-IIA recommendations. New recommendation #1
relates to the positive findings of the RESCUEicp study,11 while
new recommendation #2 relates to the negative findings of
the DECRA study.9,10 Recommendation #4 reflects findings
consistent in both studies.9-11
Evaluation of the Updated Body of Evidence
The scope of this update was limited to the addition of the
RESCUEicp study and the 12-mo DECRA outcome data to the
existing body of evidence. Following the appraisal and addition
of this evidence, we assessed whether changes to the 2017 recommendations were appropriate. The methodology and analytical
framework employed were consistent with those used for the
previously published fourth edition.12
To complete these tasks, we assembled a subcommittee
comprising a senior methodologist and 2 clinical investigators
who were authors of the DC section of the 2017 guidelines
document.12 The work of this subgroup was then presented to
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TABLE 1. Quality of the Body of Evidence

Topic
Components of overall quality–classes 1 and 2
DC vs medical management9-11
Larger DC vs smaller DC12,14

Components of overall quality–class 3
DC vs craniotomy15,16
Timing of DC17,18

Number
Metaof studies analysis

Number
of
subjects

Class of
studies

Consistency
(high,
moderate,
low)

Quality of
Precision
evidence (high,
(high,
Directness
(direct or moderate, moderate, low,
insufficient)
low)
indirect)

2 RCTs
2 RCTs

NA
No:
Different
outcomes

553
560

1
2

Moderate
Moderate

Direct
Direct

Moderate
Moderate

Moderate
Moderate

2 observational
2 observational

No

174

3

Moderate

Direct

Low

Insufficient

No

160

3

Low

Direct

Low

Insufficient

all authors of the fourth edition guidelines. The updated recommendations were then extensively discussed and revised.

SUMMARY OF ASSESSMENT TASKS

DECRA had been (see Appendix, RESCUEicp and DECRA
quality assessment). The new DECRA publication10 was similarly
evaluated, and we determined that the new information provided
about the study should not change the rating.9

Quality of the Body of Evidence
Studies of DC covered several questions (Table 1). The class
1 studies compared DC to medical management, while class
2 studies compared DCs of different sizes in terms of their
effect on patient mortality and functional outcomes. Class 3
studies addressed these questions, and also (3) compared DC to
craniotomy and (4) assessed the use of DC earlier or later in the
course of treatment.12
For the first 2 questions, the overall quality of the body
of evidence was moderate. Both RCTs that compared DC to
initial medical management were rated class 1.9-11 Because of
the important differences between these studies, there remains
a need to replicate their findings before achieving a high level
of confidence that the conclusions will not be changed with the
results of future studies. Both RCTs that compared sizes of DCs
were rated class 2.14,15 The class 3 studies on the questions of
DC vs craniotomy and the timing of DC questions were not
incorporated into the recommendations and are not included in
Table 2, given higher level evidence was available. The class 3
studies remain available for reference in the fourth edition.12

Data Abstraction
Table 2 contains updated data abstractions for the DECRA
and RESCUEicp trials. DECRA and RESCUEicp are both RCTs
that compared outcomes from patients receiving DC to outcomes
from medical management as interventions for severe TBI with
refractory ICP elevation.

Quality Assessment
Fundamental to this update was an appraisal of the level of
evidence provided by both the DECRA and the RESCUEicp
RCTs. DECRA had previously been judged to be a class I
study with an overall quality rating of “Good” (on a scale of
Good/Fair/Poor)12 as it was an RCT without multiple, serious risks
of bias. RESCUEicp underwent an independent assessment for
quality by 2 reviewers using the same instrument as used to assess
the DECRA trial and all other studies included in the fourth
edition. RESCUEicp was rated a good-quality (class I) study as

SUMMARY OF THE EVIDENCE

NEUROSURGERY

Applicability
Applicability was adjudicated and found to differ across
questions and studies. DECRA was conducted in 3 countries over
an 8-yr period and included 15 medical centers. RESCUEicp was
conducted in 20 countries over a 10-yr period and included 73
medical centers. While the diversity of patients and settings may
have limited the ability to detect an effect, it could increase the
applicability of the studies.
The 2 class 2 studies that compare sizes of DCs were both
conducted in one country (China).14,15 These publications
provide incomplete information on key details, limiting our
ability to adjudicate elements such as the standard of care and
characteristics of the studied populations.

Class 1 and 2 Studies
The characteristics and results of class 1 and 2 studies of DC
are summarized in Table 2.
Evidence Summary
The relationship between secondary DC and neurological
outcome following severe TBI has been investigated in many
studies; however, 2 RCTs provide the best evidence currently
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TABLE 2. Summary of Evidence – Class 1 and 2 Studies of Decompressive Craniectomy

Reference, study topic

Study design, N,
and outcomes

DC compared to medical management
RCT
Cooper, 2011, 20209,10
N = 155
(DECRA)
DC = 73
No DC = 82
DC vs medical
management
Mortality
Patients with ICP
> 20 mmHg for 15 min
over a 1-h period within
the first 72 h of care–
“early refractory ICP
elevation”

Extended GOS
Favorable = 5-8
Lower moderate
disability or better

Data class

Class I
29.8% potentially
eligible patients
not randomized
and no
comparison of
included to not
included (21: no
consent; 344:
excluded with no
reason reported)

Unfavorable = 1-4
Upper severe
disability or worse

Results conclusion

Mortality DC vs medical management
6 mo. 19% vs 18%
12 mo 21% vs19%
GOS-E unadjusted ORs for DC group
(no DC is the reference group)
Worse functional outcome:
6 mo: 1.84 (95% CI 1.05-3.24), P = .03
12 mo: 1.68 (95% CI 0.96-2.93), P = .07
More unfavorable outcomes:
6 mo: 2.21 (95% CI 1.14-4.26), P = .02
12 mo: 1.58 (95% CI 0.84-2.99), P = .15)
ICP reduction
Number of hours of ICP > 20 mm Hg (median) 9.2 vs
30.0 (P < .001)
Intracranial hypertension index (median) 11.5 vs19.9
(P < .001)

ICU days

GOS-E 12 mo
DC
N = 73
%
Death
21
Vegetative
11
Low severe disability
19
Upper severe disability
8
Low moderate disability
14
Upper moderate disability
19
Lower good rec
5
Upper good rec
3

Medical
N = 82
%
19
3
16
10
12
19
16
5

DC fewer ICU days during hospitalization
3(10-18) vs 18(13-24), P < .001.
12 mo exploratory analyses:
Fewer good outcomes in survivors with DC:
0.33 (95% CI, 0.12 to 0.91) P = .03

Hutchinson, 201611

RCT

(RESCUEicp)

N = 398
DC = 202
No DC = 196

DC vs medical
management

Mortality
Patients with TBI and
refractory elevated ICP
(>25 mm Hg for 1-12 h)
within 10 d of
admission–

Extended GOS
Favorable = 4-8
Upper severe
disability or better
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Class 1
Modified
intention to treat
(excluded loss to
follow-up and
withdrawal of
consent)

More vegetative outcomes in survivors with DC:
5.12 (95% CI 1.04 to 25.2) P = .04
Mortality: DC vs medical management
6 mo 16.9% vs 48.9%
12 mo 30.4% vs 52.0%
GOS-E
Favorable outcome: DC vs medical
6 mo 42.8% vs 34.6% (P = .12)
12 mo 45.4% vs 32.4% (P = .01)
GOS-E distribution
differed between groups (P < .001)
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TABLE 2. Continued

Reference, study topic
“late refractory ICP
elevation”

Study design, N,
and outcomes

Data class

Unfavorable = 1-3
Lower severe
disability or worse

Results conclusion
ICP reduction
Median duration of ICP > 25 mm Hg
after randomization—5.0 vs 17.0 (P < .001)
Median intracranial hypertension index 20 18.1 vs
31.4 (P < .001)
Median intracranial hypertension index 25 6.6 vs 11.8
(P < .001)
GOS-E 12 mo
DC
N = 185
%
Death
30.4
Vegetative
6.2
Lower severe disability
18.0
Upper severe disability
13.4
Lower moderate disability 10.3
Upper moderate disability
11.9
Lower good recovery
19.7
Upper good recovery
2.6

Medical
N = 175
%
52.0
1.7
14.0
3.9
7.8
12.3
3.9
4.5

DC “patients had fewer hours than medical patients
with ICP above 25 mm Hg after randomization
(median, 5.0 vs 17.0
h; P < .001) but had a higher rate of adverse events
(16.3% vs 9.2%”, P = .03).
Size of DC
Jiang, 200519
Comparison of the
influence of standard,
larger trauma
craniectomy
([STC] unilateral
frontotemporoparietal
bone flap [12 × 15 cm])
vs a limited, smaller
craniectomy ([LC]
temporoparietal bone
flap [6 × 8 cm])
Qiu, 200914
Unilateral DC
(larger = 15 cm
diameter) vs
unilateral routine
temporoparietal
craniectomy

RCT
N = 486
STC:245
LC: 241
GOS at 6 mo
Complications

RCT
N = 74
Unilateral DC = 37
Unilateral routine
temporoparietal
craniectomy (control
group) = 37
Mortality at 1 mo;
GOS at 1 yr
Complications

Class 2
Concern about
baseline
differences
between
eligible/excluded
and
eligible/included

Class 2
Concern about
baseline
differences
between
eligible/excluded
and
eligible/included

STC vs LC
GOS 4 or 5: good recovery or moderate deficit
96 (39.8%) vs 70 (28.6%), P = .05
GOS 2 or 3: severe deficit or vegetative state
82 (34.0%) vs 89 (36.3%), P = .05
GOS 1: death
63 (26.2%) vs 86 (35.1%), P < .05.
Significantly greater mortality in the LC group;
incidence of delayed hematoma and incision
cerebrospinal fluid fistula significantly lower in the
STC group, while other complications did not differ
Mortality at 1 mo
27% in the large DC group
57% in the smaller DC control, P = .010
Good neurological outcome (GOS score of 4-5) at 1 yr
56.8% in the large DC group vs 32.4% in the smaller DC
control, P = .035.
Incidences of delayed intracranial hematoma: 21.6% in
the large DC group vs 10.8% in the smaller DC group,
P = .041
Subdural effusion: 5.4% in the large DC group vs 0% in
the smaller DC group, P = .040
Larger DC improved outcomes (mortality and
function), but resulted in higher rates of complications
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available. The 2 studies are DECRA9,10 and RESCUEicp,11 both
providing class I evidence.
DECRA
DECRA compared outcomes for patients with diffuse brain
injury treated with early bifrontal DC to those treated with
medical management. Patients with intracranial mass lesions were
excluded from enrollment. They used 3 primary methods for
comparison. (1) They compared group differences in control of
ICP, days of mechanical ventilation, days in intensive care unit
(ICU), and mortality. (2) They used the median score for each
group on the 8-item GOS-E scale to calculate the odds of worse
outcomes. (3) They dichotomized the 8-item GOS-E scale to
calculate the odds of unfavorable outcomes.
Using group differences assessed at 6 mo postenrollment–the
primary outcome–they found the DC group had lower ICP, fewer
days on mechanical ventilation and in the ICU, and no difference
between groups for mortality. Using the median score for each
group of the GOS-E measured at 6 mo postinjury (3: DC, 4:
No DC), the unadjusted odds ratio (OR) for worse outcomes
in the DC group was 1.84 (95% CI 1.05-3.24), P = .03, but
after adjustment, the OR was no longer significant. Using the
dichotomized score (1-4 vs 5-8), both unadjusted and adjusted
odds of unfavorable outcomes were significantly greater in the DC
group.
More recently, the DECRA investigators published the
12-mo outcome data from their study. This has been highly anticipated as there is a growing sense that assessment at 6 mo may be
a premature endpoint for the severe TBI population; moreover,
it facilitates a comparison to the 12-mo outcome data provided
by RESCUEicp. Notably 12-mo outcome data were a secondary
endpoint in both trials, however.
The 12-mo outcome data from DECRA were similar to what
was noted at 6 mo. At 12 mo, there was a trend to worse functional
outcomes in the craniectomy group (OR 1.68, 95% CI 0.962.93; P = .07) as well as unfavorable functional outcomes (OR
1.58; 95% CI 0.84-2.99; P = .16), though these results were
not statistically significant as they were in the 6-mo data. An
exploratory post-hoc analysis noted that amongst survivors after
craniectomy, there were fewer good (OR 0.33; 95% CI 0.120.91; P = .03) and more vegetative (OR 5.12; 95% CI 1.04-25.2;
P = .04) outcomes.
RESCUEicp
RESCUEicp compared outcomes of patients who received
DC as a salvage treatment for ICP elevation with those who
received medical management. It tolerated ICP elevation for a
longer duration prior to enrollment than the DECRA study.
RESCUEicp was intended to study patients with intracranial
mass lesions and those undergoing lateral decompressions.
However, the study predominantly enrolled patients with diffuse
injuries, and most patients underwent bifrontal decompressions,
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making the included patients very similar to those enrolled in
DECRA.
RESCUEicp used 2 methods for comparison. (1) They
compared group differences in control of ICP, mortality, and
distribution of the GOS-E ratings. (2) They dichotomized
the 8-item GOS-E scale to compare favorable vs unfavorable
outcomes between groups. Using group differences, for the
primary outcome measured at 6 mo postinjury, there was a
lower rate of mortality and higher rate of vegetative state, lower
severe disability, and upper severe disability in patients in the
DC group. The unordered test comparing the distribution of
the GOS-E ratings over the 2 groups yielded a χ 2 of 30.69
(7 df, P < .001) (individual P values not reported). Using the
dichotomized score (1-3 vs 4-8, a different dichotomization from
that used in DECRA), 42.8% of patients in the DC group had
favorable outcomes vs 34.6% of patients in the No DC group
(P = .12). At 12 mo, this same comparison of favorable outcomes
reached statistical significance with 45.4% of patients in the DC
group with favorable outcomes vs 32.4% of patients in the No
DC group (P = .01).
As with DECRA, RESCUEicp demonstrated that DC effectively lowered ICP and reduced the duration of intensive care
management. It demonstrated an increase in the rate of poor
outcomes when comparing the distribution of GOS-E ratings,
but no difference in outcomes using the dichotomized GOS-E.
Of note, for the secondary outcome at 12 mo postinjury, significantly more patients in the DC group than the No DC group
had favorable outcomes, using the dichotomized score of GOS-E
(P = .01).
Comparability of DECRA and RESCUEicp
Comparability of the outcomes from these 2 studies is compromised by a number of factors. The design of DECRA targeted
the effects of DC as applied to early stages of resistant intracranial
hypertension, whereas RESCUEicp studied patients with more
established resistance. Time from injury to treatment was lower
in DECRA than in RESCUEicp. The ICP treatment threshold
was higher and duration of time above that threshold was
longer in RESCUEicp than in DECRA. The surgical approach
varied across the 2 studies and within RESCUEicp. Finally, they
used different cut-points for the dichotomization of GOS-E,
increasing the probability of a higher proportion of patients with
favorable outcomes in RESCUEicp.
DECRA and RESCUEicp were consistent in demonstrating
that DC reduces ICP and duration of intensive care. They
both also detected an increased rate of some levels of poor
outcomes with DC. Although it used a secondary outcome
measure with a more generous dichotomization scheme, 12-mo
data in RESCUEicp seem to indicate that the outcome
benefits of decompression continue to improve beyond the prespecified six-month test period. This same effect is suggested
in the DECRA study as the ORs had smaller magnitudes and
P-values became nonsignificant at 12 mo; however, this is best
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interpreted as a reduction in the magnitude of the harm associated
with DC. Findings related to mortality were inconsistent between
the studies with a mortality benefit noted in RESCUEicp but
none in DECRA.
The authors debated the extent to which the bifrontal surgical
procedures performed in the DECRA and RESCUEicp studies
should be extrapolated to the lateral decompressions more
popular in North America. In DECRA, bifrontal decompressions were performed exclusively, and they were performed more
commonly than lateral decompressions in RESCUEicp. Given a
lack of evidence discriminating these 2 forms of DC at this time,
we chose to provide recommendations that do not reference a
specific decompressive surgery. It will be desirable in the future,
however, to determine if there are differences in the risk:benefit
ratios of these surgeries and whether one or the other should be
applied preferentially in specific circumstances.

EXPERT OPINION
Incorporating the Evidence Into Practice
Translation of Evidence Into Practice
DC remains a very controversial topic in the TBI field. There
was much hope that the 2 key RCTs, DECRA and RESCUEicp,
would provide clarity on whether or not this is a procedure that
neurosurgeons should perform amongst other therapeutic options
available for severe TBI. Unfortunately, neither DECRA nor
RESCUEicp, together or separately, provides definitive evidence
for or against the performance of DC, and they are both
complex and challenging to interpret. Perhaps the most important
conclusion of these studies is that choosing to perform a DC is
not a simple decision and that the potential benefits should be
balanced against the complications and likely outcomes on a caseby-case basis.
Impact of Evidence on Practice
Anecdotal evidence suggests that these new RCTs have not
markedly changed practice. DC continues to be performed. This
likely reflects uncertainty in the prognosis of individual patients
as well as the fact that it is hard to withhold a possibly lifesaving therapy even when the odds of functional recovery are
believed to be low. Indeed, despite important advances in our
ability to predict prognosis on a population level for severe
TBI patients early after injury,16,17 it remains hard to accurately
predict outcomes for an individual patient.
Recent Clinical Consensus
Subsequent to the publication of RESCUEicp, a large international consensus conference was convened in an effort to
provide recommendations for the use of DC in severe TBI
care. Expert opinion and experience were used to address the
gaps in evidence. The proceedings of this conference were
recently published.18 The consensus conference concluded that
DC remains a treatment option for severe TBI patients and
that both bifrontal and lateral decompressions are reasonable to
NEUROSURGERY

perform. However, the group also agreed that DC should not
be applied indiscriminately and that additional efforts to assess
the likelihood of positive patient outcomes should be made prior
to DC. For example, preoperative magnetic resonance imaging
scans could reveal devastating structural brain lesions (such as
in the brainstem) not seen on computed tomography, which
would predict a lack of benefit from surgical decompression.
Patients with evidence of “good” brain function who decline as a
direct consequence of ICP elevation are likely the best candidates
for decompression; however, identifying such patients remains
challenging. The group also recognized that longer term outcome
measures are important in future studies commensurate with
the ongoing clinical improvements in severe TBI patients from
6 to 24 mo postinjury. These recommendations are reflected
in the inclusion of DC as a tier 3 treatment option in the
Seattle International severe traumatic Brain Injury Consensus
Conference (SIBICC) management algorithms.1,2
What Is a “Good” Outcome?
Central to the debate around the performance of DC is
the issue of what constitutes acceptable (or “good”) neurological recovery. Of additional complexity is the question of
what is acceptable precision in predicting this “acceptable”
recovery. Different cultures, families, and patients define what
is meaningful function and what makes life worth living differently; the answers to these questions are more philosophical than
medical. Given the controversy surrounding DC and the uncertainty about which patients will return to prior or meaningful
function and which will not, family members or other proxy
decision-makers familiar with patients’ values and preferences
should be provided with the best information available and
included in clinical decision making.
Future Directions
Though convincing evidence currently supports that DC
reduces ICP, and that DC of insufficient size is associated with
poor outcomes, additional high-quality studies are needed to
inform every aspect of DC as it is applied in clinical practice for
severe TBI. Several particularly important gaps in knowledge are
evident from this analysis of the body of evidence. The relative
risks and benefits of lateral DC as compared to bifrontal DC
are a critical knowledge gap. It remains to be seen if the decompression should be tailored to the intracranial pathology. For
instance, one might hypothesize that a bifrontal DC is better
suited to a patient with frontal contusions, while a lateral decompression may be preferable for those with extra-axial hematomas
but this remains uninformed by evidence. The importance of
incising the falx when a bifrontal DC is performed was questioned
in conjunction with the interpretation of the DECRA trial, but
this too remains insufficiently understood. It has been suggested
that efforts should be made to better identify patients who will
benefit from DC and that additional investigations may assist this
process.18 This should be a very high priority for ongoing and
new research efforts. There is also a growing sense that the traditional trial endpoint–the GOSE score at 6 mo–assesses outcomes
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prematurely and that longer term follow-up would be preferred in
severe TBI treatment studies. The optimal time to perform bone
flap replacement–or cranioplasty–is also insufficiently understood
at present.
It is also important to consider that current literature predominantly relates to secondary DC, in which the bone flap is removed
in a delayed fashion to treat refractory elevation of ICP. A paucity
of literature currently informs primary DC, or the practice of
leaving the bone flap off following an initial surgery to evacuate an
intracranial mass lesion. It is hoped that the ongoing RESCUESDH RCT will help inform the performance of primary DC with
high-quality data.19,20
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